帕斯特纳克给了他一个几乎无法察觉的微笑。
顾问公司贝恩咨询Bain合伙人安德鲁·帕斯特纳克(Andrew Pasternak)表示，与生产普通非专利药品相比，生产仿生物药品涉及的技术更加复杂。
The science involved in making biosimilars is much more complicated than that in making ordinary generics, says Andrew Pasternak of Bain &Company, a consultancy.
帕斯特纳克先生说生物仿制制药威胁到了现有的生物技术制药公司，如安进公司和基因泰克公司(现在已属瑞士制药巨头罗氏旗下)，他们的数十亿美元的销售目标现在都有风险。
Biosimilars threaten incumbent biotech firms such as Amgen and Genentech (now part of Roche, a Swiss drugs giant), which have billions of dollars of sales at risk, argues Mr Pasternak.
帕斯·特纳克预计，大型生物科技厂商将进行激烈抗争以捍卫其业务。
Big biotech will fight hard to defend its patch, he predicts.
帕斯·特纳克预计，大型生物科技厂商将进行激烈抗争以捍卫其业务。
Big biotech will fight hard to defend its patch, he predicts.
应用推荐